Vol. 22/No. 24 | OncologyLive

The Future of Cancer Care Depends on Trust in the Scientific Community

January 04, 2022

From the Editor

Maurie Markman, MD, shares how evidence strongly supports that approaches to cancer prevention have little chance of success unless those being targeted are willing to listen to, and ultimately trust, the recommendations being made by members of the scientific community.

Pembrolizumab Proves Potential as New Standard of Care for RCC in Adjuvant Setting

December 17, 2021

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs placebo as a postnephrectomy adjuvant therapy in patients with renal cell carcinoma at intermediate-high or high risk of recurrence, and in those who are M1 with no evidence of disease.